AstraZeneca and Bristol Myers Squibb Hold Talks for Potential Mega-Merger
AstraZeneca and Bristol Myers Squibb have entered into talks regarding a potential merger that could become the largest in pharmaceutical history. If the deal is finalized, the combined entity would be valued at approximately $400 billion, making it the world's fourth-largest drugmaker by market capitalization. While neither company has officially confirmed the report, analysts expressed skepticism regarding the timing of the move. AstraZeneca currently maintains a strong growth and innovation profile, while Bristol Myers Squibb faces upcoming patent expirations for top-selling drugs. A potential merger would create the industry's broadest oncology portfolio, though it may face significant antitrust scrutiny due to overlapping products in non-small cell lung cancer and other therapeutic areas. Market reactions were mixed, with AstraZeneca shares falling as much as 7% following the news. Conversely, Bristol Myers Squibb shares rose nearly 6% in pre-market trading. The merger could also serve as a strategic move for AstraZeneca to increase its presence in the U.S. market, where Bristol Myers Squibb derives the majority of its revenue.